Esta página se tradujo automáticamente y no se garantiza la precisión de la traducción. por favor refiérase a versión inglesa para un texto fuente.

Conceptualization and Scale Development of Excessive Emotional Behaviors

22 de junio de 2026 actualizado por: Xinghua Liu

Development and Validation of the Excessive Emotional Behaviors Scale: Long and Short Forms Among Chinese Adults With Emotional Distress

Emotional disorders, including anxiety and depression, represent a major global health burden and are increasingly conceptualized within a transdiagnostic framework. Within this framework, emotional behaviors-defined as actions driven by attempts to regulate or control emotional experiences-are considered a central mechanism underlying the development and maintenance of emotional distress. Despite their theoretical importance in models such as the Unified Protocol (UP) and the Mindfulness Intervention for Emotional Distress (MIED), there is currently no dedicated, psychometrically validated instrument specifically designed to assess excessive emotional behaviors.

The present study aims to develop and validate a self-report scale of excessive emotional behaviors grounded in the theoretical frameworks of UP and MIED. Excessive emotional behaviors are conceptualized as behaviors whose frequency, intensity, or reliance exceeds adaptive levels in response to emotional experiences and contributes to functional impairment.

A mixed-method design will be employed. Study 1 will involve semi-structured cognitive interviews with approximately 18 participants experiencing anxiety or depressive distress to evaluate item clarity, experiential relevance, and content coverage, and to refine the initial item pool. Study 2 will consist of a quantitative survey with a larger sample to examine the scale's psychometric properties, including factor structure, reliability, and validity. Exploratory factor analysis (EFA) and confirmatory factor analysis (CFA) will be conducted to establish the underlying structure of the scale. Convergent and discriminant validity will be assessed through correlations with measures of experiential avoidance (AAQ-II, BEAQ), anxiety (GAD-7), and depression (PHQ-9).

The expected outcome is a brief, reliable, and valid instrument that captures multiple dimensions of excessive emotional behaviors, such as behavioral avoidance, cognitive avoidance, safety behaviors, and emotion-driven actions. This scale will provide a theoretically grounded and clinically useful tool for transdiagnostic research, mechanism testing, and intervention evaluation in emotional disorders.

Descripción general del estudio

Tipo de estudio

De observación

Inscripción (Actual)

637

Contactos y Ubicaciones

Esta sección proporciona los datos de contacto de quienes realizan el estudio e información sobre dónde se lleva a cabo este estudio.

Ubicaciones de estudio

    • Beijing Municipality
      • Beijing, Beijing Municipality, Porcelana, 100871
        • Peking University

Criterios de participación

Los investigadores buscan personas que se ajusten a una determinada descripción, denominada criterio de elegibilidad. Algunos ejemplos de estos criterios son el estado de salud general de una persona o tratamientos previos.

Criterio de elegibilidad

Edades elegibles para estudiar

  • Adulto
  • Adulto Mayor

Acepta Voluntarios Saludables

Sí

Método de muestreo

Muestra no probabilística

Población de estudio

Adult participants will be recruited from university counseling centers and the general community through online and offline advertisements. The study population will primarily consist of individuals experiencing varying levels of emotional distress, including symptoms of anxiety and depression, as well as individuals from the general population. All participants will be able to complete self-report questionnaires in Chinese.

Descripción

Inclusion Criteria:

Aged 18 years or older Current or recent experience of significant anxiety or depressive distress Adequate ability to understand and communicate in Chinese Able and willing to provide written informed consent

Exclusion Criteria:

Acute psychotic episode or other severe psychiatric disorder that would interfere with study participation Cognitive impairment that would prevent effective participation in the study

Plan de estudios

Esta sección proporciona detalles del plan de estudio, incluido cómo está diseñado el estudio y qué mide el estudio.

¿Cómo está diseñado el estudio?

Detalles de diseño

Cohortes e Intervenciones

Grupo / Cohorte
General Adult Sample

¿Qué mide el estudio?

Medidas de resultado primarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Initial Excessive emotional Behaviors Scale
Periodo de tiempo: Baseline and 1 month

The Initial Excessive Emotional Behavior Scale (EEBS) consists of 40 items. Each item is rated on a 5-point scale, and the total score ranges from 40 to 200, with higher scores indicating more severe excessive emotional behavior and lower scores indicating fewer excessive emotional behaviors.

Subscale scores are calculated as follows:

Behavioral Avoidance: sum of Items 1-14 Cognitive Avoidance: sum of Items 15-21 Safety Signals: sum of Items 22-32 Emotion-Driven Behavior: sum of Items 33-40

The total EEBS score is obtained by summing all 40 items. Item 11 is reverse scored before computing the subscale and total scores. In addition to the total score, subscale scores may be analyzed separately to identify the individual's primary areas of difficulty.

Baseline and 1 month
The Acceptance and Action Questionnaire-II (AAQ-II)
Periodo de tiempo: Baseline and 1 month
The Acceptance and Action Questionnaire-II (AAQ-II) will be used to assess experiential avoidance and psychological inflexibility. The scale contains 7 items, each rated on a 7-point Likert scale, with a total score ranging from 7 to 49. Higher scores indicate greater experiential avoidance and psychological inflexibility, whereas lower scores indicate lower levels of experiential avoidance and greater psychological flexibility.
Baseline and 1 month
The Brief Experiential Avoidance Questionnaire (BEAQ)
Periodo de tiempo: Baseline and 1 month
The Brief Experiential Avoidance Questionnaire (BEAQ) will be used to assess experiential avoidance across multiple domains. The scale contains 15 items derived from the Multidimensional Experiential Avoidance Questionnaire (MEAQ). With each item rated on a 6-point Likert scale, the total score ranges from 15 to 90. Higher scores indicate greater experiential avoidance, whereas lower scores indicate lower levels of experiential avoidance.
Baseline and 1 month

Medidas de resultado secundarias

Medida de resultado
Medida Descripción
Periodo de tiempo
Generalized Anxiety Disorder Scale (GAD-7)
Periodo de tiempo: Baseline and 1 month
The Generalized Anxiety Disorder Scale (GAD-7) will be used to assess anxiety symptoms. The scale contains 7 items, each rated on a 4-point Likert scale, with a total score ranging from 0 to 21. Higher scores indicate more severe anxiety symptoms, whereas lower scores indicate less severe anxiety symptoms.
Baseline and 1 month
Patient Health Questionnaire (PHQ-9)
Periodo de tiempo: Baseline and 1 month
The Patient Health Questionnaire-9 (PHQ-9) will be used to assess depressive symptoms. The scale contains 9 items, each rated on a 4-point Likert scale, with a total score ranging from 0 to 27. Higher scores indicate more severe depressive symptoms, whereas lower scores indicate less severe depressive symptoms.
Baseline and 1 month

Colaboradores e Investigadores

Aquí es donde encontrará personas y organizaciones involucradas en este estudio.

Patrocinador

Fechas de registro del estudio

Estas fechas rastrean el progreso del registro del estudio y los envíos de resultados resumidos a ClinicalTrials.gov. Los registros del estudio y los resultados informados son revisados ​​por la Biblioteca Nacional de Medicina (NLM) para asegurarse de que cumplan con los estándares de control de calidad específicos antes de publicarlos en el sitio web público.

Fechas importantes del estudio

Inicio del estudio (Actual)

28 de abril de 2026

Finalización primaria (Actual)

22 de junio de 2026

Finalización del estudio (Actual)

22 de junio de 2026

Fechas de registro del estudio

Enviado por primera vez

16 de abril de 2026

Primero enviado que cumplió con los criterios de control de calidad

23 de abril de 2026

Publicado por primera vez (Actual)

30 de abril de 2026

Actualizaciones de registros de estudio

Última actualización publicada (Actual)

25 de junio de 2026

Última actualización enviada que cumplió con los criterios de control de calidad

22 de junio de 2026

Última verificación

1 de junio de 2026

Más información

Términos relacionados con este estudio

Términos MeSH relevantes adicionales

Otros números de identificación del estudio

  • E20260416

Plan de datos de participantes individuales (IPD)

¿Planea compartir datos de participantes individuales (IPD)?

NO

Descripción del plan IPD

Individual participant data (IPD) will not be publicly shared due to concerns regarding participant privacy and confidentiality. The dataset contains potentially identifiable information related to mental health status. However, reasonable requests for access to de-identified data may be considered by the corresponding author.

Información sobre medicamentos y dispositivos, documentos del estudio

Estudia un producto farmacéutico regulado por la FDA de EE. UU.

No

Estudia un producto de dispositivo regulado por la FDA de EE. UU.

No

Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .

Suscribir